Department of Biochemistry, University Alberta, Edmonton, AB T6G 2H7, Canada.
Department of Biochemistry, University Alberta, Edmonton, AB T6G 2H7, Canada; School of Life Science and Technology, Henan Institute of Science and Technology, Xinxiang 453003, PR China.
Biochim Biophys Acta Biomembr. 2021 Sep 1;1863(9):183648. doi: 10.1016/j.bbamem.2021.183648. Epub 2021 May 14.
Mammalian Na/H exchanger isoform one (NHE1) is a plasma membrane protein responsible for pH regulation in mammalian cells. Excess activity of the protein promotes heart disease and is a trigger of metastasis in cancer. Inhibitors of the protein exist but problems in specificity have delayed their clinical application. Here we examined amino acids involved in two modeled inhibitor binding sites (A, B) in human NHE1. Twelve mutations (Asp159, Phe348, Ser351, Tyr381, Phe413, Leu465, Gly466, Tyr467, Leu468, His473, Met476, Leu481) were made and characterized. Mutants S351A, F413A, Y467A, L468A, M476A and L481A had 40-70% of wild type expression levels, while G466A and H473A expressed 22% ~ 30% of the wild type levels. Most mutants, were targeted to the cell surface at levels similar to wild type NHE1, approximately 50-70%, except for F413A and G466A, which had very low surface targeting. Most of the mutants had measurable activity except for D159A, F413A and G466A. Resistance to inhibition by EMD87580 was elevated in mutants F438A, L465A and L468A and reduced in mutants S351A, Y381A, H473A, M476A and L481A. All mutants with large alterations in inhibitory properties showed reduced Na affinity. The greatest changes in activity and inhibitor sensitivity were in mutants present in binding site B which is more closely associated with TM4 and C terminal of extracellular loop 5, and is situated between the putative scaffolding domain and transport domain. The results help define the inhibitor binding domain of the NHE1 protein and identify new amino acids involved in inhibitor binding.
哺乳动物 Na/H 交换体 1 型(NHE1)是一种位于细胞质膜上的蛋白,负责调节哺乳动物细胞的 pH 值。该蛋白的过度活性会促进心脏病的发生,并引发癌症的转移。目前已有针对该蛋白的抑制剂,但由于特异性问题,其临床应用受到了阻碍。在这里,我们研究了人源 NHE1 中两个模拟抑制剂结合位点(A 位和 B 位)所涉及的氨基酸。我们共构建了 12 种突变体(Asp159、Phe348、Ser351、Tyr381、Phe413、Leu465、Gly466、Tyr467、Leu468、His473、Met476 和 Leu481)并对其进行了鉴定。突变体 S351A、F413A、Y467A、L468A、M476A 和 L481A 的表达水平为野生型的 40%70%,而 G466A 和 H473A 的表达水平为野生型的 22%30%。除了 F413A 和 G466A,大多数突变体的细胞表面定位水平与野生型 NHE1 相似,约为 50%~70%。大多数突变体都具有可测量的活性,除了 D159A、F413A 和 G466A。与野生型相比,F438A、L465A 和 L468A 突变体对 EMD87580 的抑制作用的耐药性增强,而 S351A、Y381A、H473A、M476A 和 L481A 突变体对 EMD87580 的抑制作用的敏感性降低。所有抑制特性发生较大改变的突变体的 Na+亲和力均降低。活性和抑制剂敏感性变化最大的突变体位于结合位点 B,该位点与 TM4 和细胞外环 5 的 C 端更接近,位于假定的支架结构域和运输结构域之间。该研究结果有助于确定 NHE1 蛋白的抑制剂结合结构域,并确定新的与抑制剂结合有关的氨基酸。